MX393568B - Profarmacos de carbidopa y l-dopa y metodos de uso - Google Patents

Profarmacos de carbidopa y l-dopa y metodos de uso

Info

Publication number
MX393568B
MX393568B MX2021003840A MX2021003840A MX393568B MX 393568 B MX393568 B MX 393568B MX 2021003840 A MX2021003840 A MX 2021003840A MX 2021003840 A MX2021003840 A MX 2021003840A MX 393568 B MX393568 B MX 393568B
Authority
MX
Mexico
Prior art keywords
carbidopa
disease
treat parkinson
dopa
prodrug
Prior art date
Application number
MX2021003840A
Other languages
English (en)
Spanish (es)
Other versions
MX2021003840A (es
Inventor
Alexander D Huters
Benoit Cardinal-David
Brian P Enright
Christopher P Miller
Eric A Voight
Geoff G Zhang
James Stambuli
Kassibla E Dempah
Mark A Matulenko
Peter T Mayer
Philip R Kym
Raimundo Ho
Rodger F Henry
Russell C Klix
Scott W Krabbe
Sean E Mackey
Valentino J Stella
Vincent S Chan
Xiaochun Lou
Yanbin Lao
Ye Huang
Zhi Wang
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX393568(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2021003840A publication Critical patent/MX2021003840A/es
Publication of MX393568B publication Critical patent/MX393568B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2021003840A 2014-10-21 2015-10-21 Profarmacos de carbidopa y l-dopa y metodos de uso MX393568B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462066771P 2014-10-21 2014-10-21
PCT/US2015/056686 WO2016065019A1 (en) 2014-10-21 2015-10-21 Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease

Publications (2)

Publication Number Publication Date
MX2021003840A MX2021003840A (es) 2022-06-30
MX393568B true MX393568B (es) 2025-03-24

Family

ID=54478240

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021003840A MX393568B (es) 2014-10-21 2015-10-21 Profarmacos de carbidopa y l-dopa y metodos de uso
MX2017005236A MX381069B (es) 2014-10-21 2015-10-21 Profármacos de carbidopa y l-dopa y métodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017005236A MX381069B (es) 2014-10-21 2015-10-21 Profármacos de carbidopa y l-dopa y métodos de uso.

Country Status (37)

Country Link
US (7) US9446059B2 (index.php)
EP (3) EP3569587A1 (index.php)
JP (6) JP6567049B2 (index.php)
KR (3) KR20230066484A (index.php)
CN (4) CN111454290B (index.php)
AR (1) AR102389A1 (index.php)
AU (4) AU2015335941B2 (index.php)
BR (1) BR112017008198B1 (index.php)
CA (1) CA2965379A1 (index.php)
CY (2) CY1121826T1 (index.php)
DK (1) DK3209302T3 (index.php)
ES (1) ES2739536T3 (index.php)
FI (1) FIC20230014I1 (index.php)
FR (1) FR23C1035I2 (index.php)
HR (1) HRP20191285T1 (index.php)
HU (2) HUE044115T2 (index.php)
IL (3) IL251829B (index.php)
LT (2) LT3209302T (index.php)
LU (1) LUC00304I2 (index.php)
MX (2) MX393568B (index.php)
MY (1) MY189519A (index.php)
NL (1) NL301224I2 (index.php)
NO (1) NO2023013I1 (index.php)
PH (1) PH12017500746B1 (index.php)
PL (1) PL3209302T3 (index.php)
PT (1) PT3209302T (index.php)
RS (1) RS58972B1 (index.php)
RU (2) RU2021103000A (index.php)
SA (1) SA521421115B1 (index.php)
SG (1) SG11201703170RA (index.php)
SI (1) SI3209302T1 (index.php)
SM (1) SMT201900376T1 (index.php)
TR (1) TR201908296T4 (index.php)
TW (2) TWI755257B (index.php)
UA (1) UA120437C2 (index.php)
WO (1) WO2016065019A1 (index.php)
ZA (1) ZA201702760B (index.php)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022320B2 (en) 2014-03-13 2018-07-17 Neuroderm, Ltd. Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
CN111454290B (zh) 2014-10-21 2022-12-23 艾伯维公司 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途
JP2019515908A (ja) * 2016-04-20 2019-06-13 アッヴィ・インコーポレイテッド カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
WO2017223182A1 (en) * 2016-06-22 2017-12-28 Medchem Partners, Llc. Nitric oxide donors
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US20180311238A1 (en) * 2017-04-28 2018-11-01 Saniona A/S Selective Agonist Of a6 Containing nAChRs
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
AR113908A1 (es) 2017-11-24 2020-06-24 H Lundbeck As Profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
CN110294789A (zh) * 2018-03-21 2019-10-01 海南大学 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用
CN112770734B (zh) 2018-09-13 2024-08-20 堪培拉大学 抑制方法
TW202031265A (zh) * 2018-11-15 2020-09-01 美商艾伯維有限公司 用於皮下投藥之醫藥調配物
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
JP7514859B2 (ja) 2019-05-21 2024-07-11 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
US12391650B2 (en) 2019-05-21 2025-08-19 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
CN113727979B (zh) 2019-05-21 2024-09-20 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
WO2020234277A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4016288A (en) * 1975-08-13 1977-04-05 Merck & Co., Inc. Compositions and method of treating hypertension
DD230865B1 (de) * 1982-08-09 1987-05-20 Dresden Arzneimittel Verfahren zur herstellung von hydrazinocarbonsaeurederivaten durch n-aminierung von aminocarbonsaeurederivaten
US4508706A (en) * 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
IT1213182B (it) * 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
US4616484A (en) 1984-11-30 1986-10-14 Kysor Industrial Corporation Vehicle refrigerant heating and cooling system
IT1200427B (it) 1985-03-22 1989-01-18 Afros Spa Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
ATE118216T1 (de) * 1989-04-20 1995-02-15 Zambon Spa Dopamin-medikament-vorstufe.
GB9102812D0 (en) 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6576766B1 (en) * 1997-11-12 2003-06-10 Ariad Pharmaceuticals, Inc. Signal transduction inhibitors, compositions containing them
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
KR20050016449A (ko) * 2002-05-29 2005-02-21 임팩스 라보라토리즈, 인코포레이티드 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형
EP1541579A1 (en) 2002-06-20 2005-06-15 Nippon Suisan Kaisha, Ltd. Produrg, medicinal utilization thereof and process for producing the same
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
EP1596808A4 (en) 2003-02-07 2007-04-04 Yissum Res Dev Co L-DOPA AMID DERIVATIVES AND THEIR USE
DE602004031134D1 (de) 2003-08-29 2011-03-03 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
US20060094782A9 (en) 2003-10-31 2006-05-04 Wong Patrick S Compositions and dosage forms for enhanced absorption
DK1751087T3 (da) 2004-06-04 2012-07-16 Xenoport Inc Levodopa-derivater og sammensætninger og anvendelser deraf
WO2006014282A2 (en) 2004-07-06 2006-02-09 Abbott Laboratories Prodrugs of hiv protease inhibitors
DK1959948T3 (da) * 2005-12-05 2012-08-20 Xenoport Inc Levodopa prodrug-mesylat, sammensætninger deraf og anvendelser deraf
KR20090057349A (ko) * 2006-05-31 2009-06-05 솔베이 파머슈티컬스 게엠베하 레보도파／칼비도파의 ２４시간의 장기간 장내투여
JP2009539942A (ja) * 2006-06-16 2009-11-19 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ビフェプルノックス及びｌ−ｄｏｐａを含む組み合わせ製剤
EP2125702A1 (en) 2006-12-21 2009-12-02 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
GB0713189D0 (en) 2007-07-06 2007-08-15 Proximagen Ltd Amino acid derivatives
ATE510537T1 (de) * 2008-02-06 2011-06-15 Wockhardt Research Center Pharmazeutische zusammensetzungen von entacapon, levodopa und carbidopa mit verbesserter bioverfügbarkeit
EP2291348A4 (en) 2008-05-20 2013-05-15 Neurogesx Inc WATER-SOLUBLE ACETAMINOPHENANALOGA
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
MX2011012315A (es) 2009-05-19 2011-12-16 Neuroderm Ltd Composiciones para la administracion continua de inhibidores de dopa descarboxilasa.
US8435562B2 (en) 2009-11-09 2013-05-07 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
WO2011109767A2 (en) 2010-03-04 2011-09-09 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
EP3326615B1 (en) 2010-11-15 2020-01-08 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
JP5423905B2 (ja) 2010-12-02 2014-02-19 小野薬品工業株式会社 新規化合物及びその医薬用途
CA2823642A1 (en) 2010-12-10 2012-06-14 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
US8765189B2 (en) * 2011-05-13 2014-07-01 Howmedica Osteonic Corp. Organophosphorous and multivalent metal compound compositions and methods
KR20130070371A (ko) * 2011-12-19 2013-06-27 울산대학교 산학협력단 퇴행성 신경질환 예방 또는 치료용 조성물
PT2968218T (pt) 2013-03-13 2021-09-24 Neuroderm Ltd Combinação para tratamento da doença de parkinson
WO2014139161A1 (en) 2013-03-15 2014-09-18 Techfields Pharma Co., Ltd. Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases
CN111454290B (zh) * 2014-10-21 2022-12-23 艾伯维公司 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
JP2019515908A (ja) 2016-04-20 2019-06-13 アッヴィ・インコーポレイテッド カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
WO2018059739A1 (en) 2016-09-29 2018-04-05 Berlirem Gmbh L-dopa derivatives for the treatment of neurological diseases
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions

Also Published As

Publication number Publication date
FIC20230014I1 (fi) 2023-03-31
LT3209302T (lt) 2019-06-10
TW202131931A (zh) 2021-09-01
US20180079762A1 (en) 2018-03-22
SMT201900376T1 (it) 2019-09-09
JP2025118978A (ja) 2025-08-13
CN111362980A (zh) 2020-07-03
AU2025238004A1 (en) 2025-10-16
KR20170071599A (ko) 2017-06-23
RU2021103000A (ru) 2021-03-01
JP7688087B2 (ja) 2025-06-03
US9446059B2 (en) 2016-09-20
KR20230066484A (ko) 2023-05-15
IL268885B (en) 2020-08-31
EP4186510A1 (en) 2023-05-31
TWI718999B (zh) 2021-02-21
MX2021003840A (es) 2022-06-30
US10730895B2 (en) 2020-08-04
AU2021201414A1 (en) 2021-03-25
HUE044115T2 (hu) 2019-10-28
CY2023010I2 (el) 2023-06-09
DK3209302T3 (da) 2019-05-13
JP2017537066A (ja) 2017-12-14
JP2020189864A (ja) 2020-11-26
HUS2300009I1 (hu) 2023-03-28
UA120437C2 (uk) 2019-12-10
RU2017117413A3 (index.php) 2019-05-30
PT3209302T (pt) 2019-07-19
LTC3209302I2 (index.php) 2025-10-10
IL276493A (en) 2020-09-30
NL301224I1 (index.php) 2023-03-29
WO2016065019A1 (en) 2016-04-28
LUC00304I2 (index.php) 2025-09-22
BR112017008198A2 (pt) 2017-12-26
PH12017500746B1 (en) 2021-12-15
US20220153765A1 (en) 2022-05-19
AU2015335941A1 (en) 2017-05-04
JP6567049B2 (ja) 2019-08-28
RS58972B1 (sr) 2019-08-30
US11091507B2 (en) 2021-08-17
MY189519A (en) 2022-02-16
RU2017117413A (ru) 2018-11-26
EP3209302B1 (en) 2019-04-24
SI3209302T1 (sl) 2019-06-28
CY1121826T1 (el) 2020-07-31
NZ730996A (en) 2024-04-26
BR112017008198B1 (pt) 2021-02-09
KR20240113982A (ko) 2024-07-23
US20230106081A1 (en) 2023-04-06
FR23C1035I1 (fr) 2023-12-08
CA2965379A1 (en) 2016-04-28
EP3209302A1 (en) 2017-08-30
AU2023210650A1 (en) 2023-08-24
CN111494395B (zh) 2024-06-21
RU2743347C2 (ru) 2021-02-17
TWI755257B (zh) 2022-02-11
NL301224I2 (nl) 2023-08-16
IL268885A (en) 2019-10-31
CN111454290A (zh) 2020-07-28
CN111362980B (zh) 2022-10-18
FR23C1035I2 (fr) 2025-04-18
CN107206013A (zh) 2017-09-26
ZA201702760B (en) 2022-05-25
US20190375770A1 (en) 2019-12-12
CN111454290B (zh) 2022-12-23
LTPA2023519I1 (index.php) 2023-06-26
JP2019218356A (ja) 2019-12-26
PL3209302T3 (pl) 2019-10-31
AR102389A1 (es) 2017-02-22
CN111494395A (zh) 2020-08-07
US20200262852A1 (en) 2020-08-20
US10174061B2 (en) 2019-01-08
SG11201703170RA (en) 2017-05-30
TW201630924A (zh) 2016-09-01
EP3569587A1 (en) 2019-11-20
IL251829A0 (en) 2017-06-29
NZ769153A (en) 2024-04-26
IL251829B (en) 2019-09-26
HRP20191285T1 (hr) 2019-10-18
JP2023174770A (ja) 2023-12-08
JP6750076B2 (ja) 2020-09-02
TR201908296T4 (tr) 2019-06-21
PH12017500746A1 (en) 2017-10-30
MX2017005236A (es) 2017-07-26
MX381069B (es) 2025-03-12
US20160362431A1 (en) 2016-12-15
KR102537018B1 (ko) 2023-05-30
ES2739536T3 (es) 2020-01-31
AU2015335941B2 (en) 2021-04-01
AU2021201414B2 (en) 2023-05-11
NO2023013I1 (no) 2023-03-20
JP6932227B2 (ja) 2021-09-08
SA521421115B1 (ar) 2022-03-01
CY2023010I1 (el) 2023-06-09
JP2021183628A (ja) 2021-12-02
US20160106765A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
PH12017500746B1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
WO2017184871A9 (en) Carbidopa and l-dopa prodrugs and methods of use
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
EP4364743A3 (en) A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
MX2021010886A (es) Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson.
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
ZA202002626B (en) Use of riluzole prodrugs to treat ataxias
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2020005707A (es) Profarmacos de creatina, composiciones y metodos de uso de estos.
EP3881845A3 (en) Combination of trazodone and gabapentin for the treatment of pain
IN2014DE00822A (index.php)
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci